|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
02.03.26 - 22:06
|
Cerus Corporation Announces Full-Year and Fourth Quarter 2025 Financial Results (Business Wire)
|
|
|
2025 Total Revenue of $233.8 million, up 16% from 2024; 2025 Product Revenue of $206.1 million, up 14% from 2024
Strengthened Financial Foundation Through Strong Commercial Execution and Disciplined Operational ManagementCONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today financial results for its full year and fourth quarter ended December 31, 2025.
“Our strong 2025 results reflect our disciplined execution, as we continued to deliver on our mission of safeguarding the world's blood supply. This past year, we achieved our highest annual kit shipments, enabling an estimated 600,000 patients worldwide to receive INTERCEPT-treated blood components,” said William “Obi” Greenman, Cerus' president and chief executive officer. “This translated into record product revenue of over $206 million, a narrowing of our GAAP net loss, and positive non-GAAP adjusted EBITDA for the second consecutive year. Looking ahead to 2026, we remain focused on improving global access to our...
|
|
|
|
|
|
|
17.02.26 - 22:03
|
Cerus Corporation to Release Fourth Quarter and Full-Year 2025 Financial Results on March 2, 2026 (Business Wire)
|
|
|
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today its fourth quarter and full-year 2025 financial results will be released on Monday, March 2, 2026, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET, during which management will discuss the Company's financial results and provide a general business overview and outlook.
To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at http://ir.cerus.com. Participants may register for the call here. While not required, interested participants are encouraged to join 10 minutes prior to the start of the event.
A replay will be available on Cerus' website and will be available approximately three hours after the call through March 23, 2026.
ABOUT CERUS
Cerus Corporation is dedicated solely to safeguarding the world's blood supply and aims to become the preeminent global blood products company. Headquartered...
|
|
|
|
|
11.01.26 - 22:03
|
Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2025 Product Revenue and Provides Outlook (Business Wire)
|
|
|
Preliminary Full-Year 2025 Product Revenue of $206.1 Million
Full-Year 2026 Product Revenue Expected to be $224 Million to $228 Million, Reflecting 9%-11% Growth, Year-Over-YearCONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced preliminary product revenue for the fourth quarter and full-year 2025, as well as provided 2026 product revenue guidance and select milestones for 2026.
“2025 was a remarkable year for Cerus, as patient access to INTERCEPT treated blood components increased meaningfully around the world,” said William “Obi” Greenman, Cerus' president and chief executive officer. “During 2025, based on the number of kits sold, we helped our blood center customers produce approximately 3 million INTERCEPT treated blood component doses for patients in about 40 countries worldwide. We remain focused on supporting blood centers around the globe in their daily mission to ensure robust blood safety and availability. We expect 2026 to be a year rich in milestones ...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
